RGD-Based Molecular Imaging: A New Tool for “Vascular Check-ups” in Lung Cancer — Imaging Strategies Targeting Integrin αvβ3 and Recommended Aladdin RGD Peptides, Antibodies and Linkers
RGD-Based Molecular Imaging: A New Tool for “Vascular Check-ups” in Lung Cancer — Imaging Strategies Targeting Integrin αvβ3 and Recommended Aladdin RGD Peptides, Antibodies and Linkers
Lung Cancer and Angiogenesis: Why Focus on “Neovasculature”?
Worldwide, lung cancer has consistently ranked among the leading malignancies in terms of both incidence and mortality, and remains one of the most important threats to human health. Non–small cell lung cancer (NSCLC) accounts for roughly 80% of all lung cancers. Although surgery, radiotherapy, chemotherapy and targeted therapies have continued to advance, overall long-term survival remains far from satisfactory.
For a tumour to sustain growth and eventually metastasise, it must secure a continuous supply of oxygen and nutrients, which largely depends on the formation of new blood vessels, i.e. angiogenesis. In solid tumours such as lung cancer, neovasculature is typically increased in number and structurally abnormal, and is regarded as a key biological basis for tumour aggressiveness and the speed of progression.
If we could visualise how active these newly formed vessels are, we would be able to understand the “vitality” of the tumour earlier and more comprehensively, and more easily assess:
1. Is the lesion malignant or benign?
2. Is the tumour progressing rapidly?
3. Are anti-angiogenic therapies, radiotherapy and chemotherapy working effectively?
This is the fundamental rationale for angiogenesis-targeted molecular imaging.
RGD and Integrin αvβ3: The “Lock and Key” on Tumour Vessels
On the surface of tumour neovasculature, there is an important protein called integrin αvβ3. Its expression is low in quiescent, normal blood vessels, but markedly upregulated on newly formed tumour vessels and on the surface of certain tumour cells. It is therefore considered one of the hallmark indicators of “active angiogenesis”.
RGD is a short peptide motif composed of three amino acids:
R = Arginine (Arg)
G = Glycine (Gly)
D = Aspartic acid (Asp)
Many extracellular matrix proteins contain this RGD sequence. Functionally, these RGD motifs act like tiny “keys” that can fit into integrin “locks” such as αvβ3, enabling specific recognition and binding. At the same time, the RGD sequence is a shared recognition motif for several integrins (e.g. αvβ3, α5β1). Many preclinical and clinical RGD-based tracers, after structural optimisation, exhibit high affinity for αvβ3 and are therefore widely used as molecular markers of active angiogenesis.
RGD peptides have several features that make them particularly suitable as imaging probes:
1. Small molecular size and well-defined structure, enabling straightforward chemical synthesis and modification;
2. High affinity for integrin αvβ3, with relatively specific binding;
3. Rapid in vivo clearance, low background signal and good image contrast.
As a result, a commonly adopted strategy is:
Attach a radionuclide to an RGD peptide → inject it into the body → perform PET/CT or SPECT/CT imaging → observe where the tracer predominantly accumulates, thereby inferring where angiogenesis is most active.
It should be noted that integrin αvβ3 is not only expressed on vascular endothelial cells; some tumour cells themselves can also express high levels of αvβ3. Consequently, RGD imaging reflects “angiogenesis + activity of a subset of tumour cells”, and is not strictly equivalent to a “pure vascular signal”.
What Can RGD Molecular Imaging Actually Show?
Compared with the more familiar ^18F-FDG PET/CT, RGD imaging can be illustrated with a simple analogy:
(a) ^18F-FDG PET: Primarily visualises “how ravenously the tumour consumes sugar” (glucose metabolism). However, inflammatory and infectious lesions can also be highly glycolytic, which may lead to false-positive findings.
(b) RGD-based molecular imaging: Is more focused on “how aggressively the tumour is building new roads (forming blood vessels)” (integrin αvβ3 expression and angiogenesis). Some studies suggest that, under certain conditions, RGD imaging may be more helpful for distinguishing tumours from inflammatory lesions and for the early assessment of treatment response.
For lung cancer, the potential value of RGD imaging mainly lies in the following aspects:
1. Supporting Diagnosis and Staging
(a) Assisting in differentiating benign from malignant pulmonary nodules;
(b) Helping to evaluate lymph node metastasis, thereby informing decisions on the extent of surgical resection.
2. Assessing the Activity of Angiogenesis
(a) Reflecting the extent and activity of intratumoral neovascularisation;
(b) Serving as an indirect indicator of tumour aggressiveness.
3. Monitoring Treatment Response and Predicting Prognosis
(a) For anti-angiogenic therapies and concurrent chemoradiotherapy, a marked decrease in RGD signal before and after treatment often indicates that angiogenesis has been suppressed and that the treatment is effective;
(b) Some studies have found that baseline RGD uptake levels may be associated with progression-free survival (PFS) and overall survival (OS), thereby contributing to prognostic assessment.
Latest Developments: What Are ^18F-Alfatide and 99mTc-3PRGD2?
In the field of lung cancer, ^18F-labelled RGD PET tracers and 99mTc-labelled RGD SPECT tracers are currently the two most intensively studied categories.
^18F-Alfatide / Alfatide II: A “Star Player” among Domestic RGD PET Tracers
The Alfatide series consists of ^18F-labelled RGD dimers (commonly referred to as ^18F-ALF-NOTA-PRGD2, ^18F-Alfatide II, etc.) developed by Chinese research teams, specifically designed to target integrin αvβ3. Early clinical studies in lung cancer patients have demonstrated that:
1. Primary lung tumours and some metastatic lesions show pronounced tracer uptake;
2. The tracer exhibits high sensitivity and specificity for the diagnosis of lymph node metastases;
3. Background uptake in normal tissues is relatively low, resulting in good image contrast.
Subsequent studies have shown that using ^18F-Alfatide II to assess tumour angiogenesis before treatment can help predict short-term response and survival outcomes—such as progression-free survival and overall survival—in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy.
More importantly, ^18F-Alfatide injection is currently being evaluated in multicentre phase III clinical trials. The main objective is to compare it with ^18F-FDG PET/CT to determine whether, for the diagnosis of lymph node metastases in NSCLC, ^18F-Alfatide is non-inferior or even superior. If these studies progress successfully, they may pave the way for RGD PET imaging to enter routine clinical practice.
99mTc-3PRGD2: A Cost-Effective SPECT Option
For many hospitals and patients, PET/CT examinations are relatively expensive, whereas SPECT/CT systems are more widely available and the associated costs are lower.
99mTc-3PRGD2 is an RGD-based tracer labelled with 99mTc that can be used for SPECT/CT imaging. Multicentre clinical studies have shown that:
1. It provides high sensitivity and specificity in the diagnosis of primary lung cancers;
2. It offers particularly high specificity in assessing intrathoracic lymph node metastases and can serve as a powerful complement to ^18F-FDG PET/CT;
3. It has a favourable safety profile and is well tolerated, providing a solid basis for further clinical implementation;
4. Ongoing prospective, multicentre phase III clinical trials are focusing on its value in the localisation and diagnosis of lymph node metastases in lung cancer.
For hospitals with relatively good equipment but without routine access to PET, 99mTc-3PRGD2 has the potential to offer a relatively economical and practical solution for imaging angiogenesis in lung cancer.
Emerging Trend: Multi-Target and Multi-Modal Approaches
Beyond “pure” RGD tracers, researchers are also exploring combinations of RGD with other molecular targets. For example, RGD has been combined with fibroblast activation protein (FAP) to generate novel tracers such as ^68Ga-FAPI-RGD, with the aim of simultaneously visualising tumour cells, tumour stroma and angiogenesis in a single imaging session.
These multi-target tracers are still in the exploratory research stage, but they represent an important future direction: obtaining multiple layers of biological information from one examination.
Current Limitations and Future Perspectives
Although RGD-based molecular imaging in lung cancer is a very active area of research, several practical issues need to be acknowledged.
1. Not a “universal tumour detector”
(a) RGD mainly reflects the expression of integrin αvβ3, which is associated with angiogenesis and the activity of a subset of tumour cells.
(b) In certain tumour types or in some patients, αvβ3 expression is intrinsically low, and in these settings the diagnostic value of RGD imaging is limited.
2. Cannot fully replace ^18F-FDG
(a) ^18F-FDG remains the “gold standard” for metabolic imaging in lung cancer.
(b) A more appropriate strategy is to use FDG and RGD in a complementary manner—FDG to assess tumour metabolism, and RGD to characterise angiogenesis and invasiveness—thereby providing clinicians with multi-dimensional information.
3. Tracers and imaging workflows are still being optimized
(a) How to make tracer synthesis more robust and easier to perform;
(b) How to reduce non-specific uptake and minimise radiation exposure to patients;
(c) How to integrate artificial intelligence and quantitative analysis to translate imaging signals more accurately into meaningful biological indicators.
4. Uptake in inflammatory and reparative tissues
(a) Although RGD imaging predominantly reflects αvβ3-related angiogenesis and tumour activity, there can also be uptake in inflammatory lesions with active neovascularisation and in healing tissues. Therefore, RGD uptake should not be simplistically equated with malignancy.
5. Regulatory and approval status
(a) At present, tracers such as ^18F-Alfatide and 99mTc-3PRGD2 are mainly in the stage of clinical trials or registry studies, and have not yet, like ^18F-FDG, become routine imaging agents across clinical practice.
Outlook
Looking ahead:
1. As domestic RGD tracers such as ^18F-Alfatide and 99mTc-3PRGD2 advance into phase III clinical trials, they are expected to be used increasingly in routine clinical practice in China.
2. For researchers and students, RGD imaging offers an excellent example of how molecular biology, imaging science and clinical decision-making can be tightly integrated.
3. For patients and their families, if their doctor mentions “RGD imaging” or “integrin-targeted imaging” in the future, it can be understood as a way of assessing how actively the tumour is “building new roads (new blood vessels)” and whether treatment is successfully “choking off” these newly formed vascular routes.
Disclaimer: This article is intended as a scientific and technical overview for educational purposes only and does not constitute any form of individual medical advice. For decisions regarding specific examinations or treatments, please follow the personalised evaluation and recommendations of qualified healthcare professionals.
Recommended Aladdin Products
Ligands and Tools Related to RGD / Integrin αvβ3
Category | Product Name | Aladdin Cat. No. | Grade & Purity | CAS No. | Typical Applications |
Linear RGD peptide | RGD peptide (GRGDNP) (TFA) | ≥97% | 114681-65-1 | Classical linear RGD sequence (Gly-Arg-Gly-Asp-Asn-Pro). Can be used as a model peptide for integrin–RGD interaction studies, including cell adhesion assays and signalling studies involving αvβ3/α5β1 pathways. After further modification, it can serve as a core scaffold (“parent” structure) for the development of radiolabeled or fluorescent RGD probes. | |
Cyclic RGD peptide | Cyclo(-RGDfK) | ≥95% | 161552-03-0 | Classical cyclic RGD peptide with high affinity for integrin αvβ3. Commonly used in studies of tumour angiogenesis and αvβ3-related signalling pathways, as well as in the design of molecular imaging probes and targeted drug delivery systems. | |
Acrylated RGD peptide | Acrylated RGD peptide (RGDfk-AA) | ≥95% (SEC-HPLC) | – | Acrylate-modified, photosensitive RGD peptide that can be crosslinked with photoresponsive polymers (e.g. hydrogels containing double bonds or norbornene (NB) structures). Suitable for RGD functionalisation of hydrogels / 3D cell culture substrates, construction of biomimetic ECM, enhancement of cell adhesion and spreading, and in vitro modelling of the tumour angiogenesis microenvironment. | |
Extracellular matrix protein | Vitronectin from Human Plasma | BioReagent, native, ≥95% (SDS-PAGE) | 83380-82-9 | Vitronectin contains an RGD motif and is an important natural ligand for integrins such as αvβ3. Frequently used to coat cultureware and to build ECM-like microenvironments for studying tumour cell and endothelial cell adhesion/migration. Well suited for use in “RGD–integrin–angiogenesis” experimental systems to mimic tumour stroma. | |
Integrin-binding peptide G4RGDSP | G4RGDSP, integrin-binding peptide | ≥99% | 774577-43-4 | Integrin-binding peptide containing an RGD motif, representing another RGD fragment used in adhesion/migration models. In teaching and basic research, it can be used alongside GRGDNP and Cyclo(-RGDfK) to compare how different RGD structures affect cell behaviour and αvβ3 binding strength. | |
Anti-αv integrin antibody / functional blocker | Abituzumab (anti-ITGAV) | Animal component-free, carrier-free, recombinant, ExactAb™ validated, low endotoxin, sodium azide-free, ≥95% (SDS-PAGE & SEC-HPLC) | 1105038-73-0 | Humanised monoclonal antibody against ITGAV (integrin αv), capable of inhibiting signalling mediated by αv-containing integrins (including αvβ3). Reported in the literature for functional studies in cancer and other diseases. Can be used together with RGD peptides in blocking experiments to confirm whether imaging or functional signals truly originate from αv integrins. | |
DOTA-PEG linker / metal chelator | DOTA-PEG5-C6-DBCO | ≥98% | – | Linker combining DOTA (for chelation of metal radionuclides such as ^68Ga and ^177Lu) and DBCO (for copper-free click reactions with azides). Suitable for conjugating RGD peptides, FAP inhibitors and other azide-containing small molecules/peptides to radiometal chelates for the construction of RGD-based or FAPI–RGD-type tracers. | |
Cu(I)-stabilising ligand / click chemistry | BTTAA, a Cu(I)-stabilising ligand | ≥99% | 1334179-85-9 | Highly efficient ligand for CuAAC click reactions that markedly enhances Cu(I)-catalysed alkyne–azide cycloaddition and reduces cytotoxicity. Well suited for the construction of RGD-based fluorescent probes, RGD–drug conjugates and RGD–chelator imaging tracers. |
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
2. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–687.
3. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.
4. Haubner R. Imaging of integrin αvβ3 expression. Cancer Metastasis Rev. 2008;27(4):567–577.
5. Haubner R, Finkenstedt A, Steiger K, et al. PET imaging of integrin αVβ3 expression. Theranostics. 2011;1:48–57.
6. Liolios C, Sachpekidis C, Kolocouris A, Dimitrakopoulou-Strauss A, Bouziotis P. PET diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin αvβ3 receptors. Molecules. 2021;26(7):1792.
7. Li L, Chen X, Yu J, Yuan S. Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors. Front Oncol. 2022;12:898764.
8. van Loon J, van Baardwijk A, Boersma L, et al. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat Rev. 2011;37(5):331–343.
9. Wan W, Guo N, Pan D, et al. First experience of ^18F-Alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54(5):691–698.
10. Wei Y, Qin X, Liu X, et al. Tumor angiogenesis at baseline identified by ^18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Transl Med. 2022;20(1):63.
11. Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53(5):716–722.
12. Wang R, Jakobsson V, Wang J, et al. Dual targeting PET tracer [^68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. Theranostics. 2023;13(9):2979–2992.
13. Zang J, Wen X, Lin R, et al. Synthesis, preclinical evaluation, and radiation dosimetry of a dual-targeting PET tracer [^68Ga]Ga-FAPI-RGD. Theranostics. 2022;12(16):7180–7196.
14. Liu N, Wan Q, Wu X, et al. A comparison of [^18F]AlF- and ^68Ga-labeled dual-targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging. Eur J Nucl Med Mol Imaging. 2024;51(5):1389–1402.
15. Mladin R, Oancea C, Stoicescu ER, et al. The role of ^18F-FDG PET/CT in monitoring immunotherapy response in non-small cell lung cancer: current evidence and challenges—a narrative review. Diagnostics (Basel). 2025;15(21):2754.
16. Ayeni A, Evbuomwan O, Vangu MDW. The role of ^18F-FDG PET/CT in monitoring of therapy response in lung cancer. Semin Nucl Med. 2025;55(2):175–189.
Aladdin: https://www.aladdinsci.com/